Basilea Pharmaceutica
PharmaBasel, Switzerland, Switzerland · Est. 2000 · 630 employees
Basilea Pharmaceutica is a Swiss biopharmaceutical company focused on developing and commercializing innovative drugs for oncology and infectious diseases.
3
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
1
Indications↗
Distinct diseases across all programs
63
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
Pipeline Snapshot
By Phase
3 drugs in development
Phase 13
By Therapeutic Area
top 0
No TA breakdown available.
R&D Momentum
27/100
Pipeline Velocity
6/100
Trial Completion Rate
87/100
Pipeline Concentration
100/100
Pipeline Freshness
87/100
Activity
Recent Activity
Last 14 days
Sep 19, 2026
Completed
A Randomized, Double-blind, Multicenter Study to Establish the Safety and Efficacy of Ceftobiprole Medocaril Compared With Vancomycin Plus Aztreonam in the Treatment of Acute Bacterial Skin and Skin Structure Infections
Sep 15, 2026
Recruiting
An Interventional Efficacy and Safety Phase 3 Double-blind 2-arm Study to Investigate IV Followed by Oral Fosmanogepix Compared With IV Caspofungin Followed by Oral Fluconazole in Adult Participants With Candidemia and/or Invasive Candidiasis
Sep 15, 2026
Recruiting
An Interventional Phase 3, Open-label, Two-cohort Study to Investigate the Efficacy and Safety of Fosmanogepix in Adult Patients With Invasive Mold Infections Caused by Aspergillus Spp., Fusarium Spp., Lomentospora Prolificans, Mucorales Fungi, or Other Multidrug Resistant Molds
Sep 15, 2026
Recruiting
A First-in-Human, Randomized, Dose-escalation, Double-blind, Placebo-controlled Study to Investigate Safety, Tolerability, and Pharmacokinetics of BAL2420 Administered to Healthy Adult Subjects
Earlier
Aug 25, 2026TrialA Phase 1, Open-label Study to Evaluate the Safety and Plasma and Intrapulmonary Pharmacokinetics of Ceftibuten and Ledaborbactam in Healthy Adult Participants
Jul 10, 2026TrialA Phase 1, Open-label Study to Evaluate the Safety and to Characterize the Pharmacokinetics of a Fixed-Dose Combination Formulation of Ceftibuten-Ledaborbactam Etzadroxil
Apr 14, 2025TrialA Study of Fosmanogepix in Healthy Adult Chinese Subjects
Jan 17, 2025TrialA Study to Assess the Effect of Ceftobiprole on the PK of Pitavastatin and on Plasma Levels of Coproporphyrin
4 more events
Aug 6, 2023TrialLate-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
Oct 31, 2022TrialA Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
Oct 12, 2022TrialCeftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function
Sep 13, 2022TrialFood Effect on Ceftibuten/VNRX-7145 in Healthy Participants
Details
Company Info
Company Overview
—
Mkt Cap
$300.0M
Revenue
—
Cash
CEOJemiljaren Mahmood
Founded2000
Employees630
HQBasel, Switzerland, Switzerland
Websitebasilea.com
LinkedInCompany Page
Therapeutic Focus
OncologyBacterial infectionsInvasive fungal infections
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)